losartan has been researched along with Cancer of Lung in 8 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
| Excerpt | Relevance | Reference |
|---|---|---|
| "Tumor metastasis would seriously impair the efficacy of chemotherapy." | 5.43 | Suppression for lung metastasis by depletion of collagen I and lysyl oxidase via losartan assisted with paclitaxel-loaded pH-sensitive liposomes in breast cancer. ( Cun, X; Gao, H; He, Q; Lu, L; Wang, Y; Xia, T; Yang, Y; Yu, Q; Zhang, L; Zhang, Q; Zhang, Z, 2016) |
| "We performed a prospective, randomized clinical study to assess whether prophylactic treatment with metoprolol or losartan, initiated soon after lung cancer surgery in patients with elevated N-terminal pro-brain natriuretic peptide (NT-proBNP) levels, reduces the incidence of postoperative atrial fibrillation." | 5.22 | Prevention of Atrial Fibrillation in High-risk Patients Undergoing Lung Cancer Surgery: The PRESAGE Trial. ( Bacchiani, G; Beggiato, M; Cardinale, D; Casiraghi, M; Cipolla, CM; Civelli, M; Colombo, A; Colombo, N; Lamantia, G; Meroni, CA; Salvatici, M; Sandri, MT; Spaggiari, L; Tedeschi, I; Veglia, F; Venturino, M, 2016) |
| "We evaluated the involvement of angiotensin II (AngII)-dependent pathways in melanoma growth, through the pharmacological blockage of AT1 receptor by the anti-hypertensive drug losartan (LOS)." | 3.76 | Inhibition of angiotensin II receptor 1 limits tumor-associated angiogenesis and attenuates growth of murine melanoma. ( Chammas, R; Freitas, HC; Fujihara, CK; Machado, CM; Mattar, AL; Nonogaki, S; Otake, AH; Zatz, R, 2010) |
| "Tumor metastasis would seriously impair the efficacy of chemotherapy." | 1.43 | Suppression for lung metastasis by depletion of collagen I and lysyl oxidase via losartan assisted with paclitaxel-loaded pH-sensitive liposomes in breast cancer. ( Cun, X; Gao, H; He, Q; Lu, L; Wang, Y; Xia, T; Yang, Y; Yu, Q; Zhang, L; Zhang, Q; Zhang, Z, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shen, Y | 1 |
| Wang, X | 1 |
| Lu, J | 1 |
| Salfenmoser, M | 1 |
| Wirsik, NM | 1 |
| Schleussner, N | 1 |
| Imle, A | 1 |
| Freire Valls, A | 1 |
| Radhakrishnan, P | 1 |
| Liang, J | 1 |
| Wang, G | 1 |
| Muley, T | 1 |
| Schneider, M | 1 |
| Ruiz de Almodovar, C | 1 |
| Diz-Muñoz, A | 1 |
| Schmidt, T | 1 |
| Li, W | 1 |
| Li, S | 1 |
| Chen, IX | 1 |
| Liu, Y | 1 |
| Ramjiawan, RR | 1 |
| Leung, CH | 1 |
| Gerweck, LE | 1 |
| Fukumura, D | 1 |
| Loeffler, JS | 1 |
| Jain, RK | 1 |
| Duda, DG | 1 |
| Huang, P | 1 |
| Hu, C | 1 |
| Liu, X | 1 |
| Ran, W | 1 |
| Meng, J | 1 |
| Zhai, Y | 1 |
| Zhang, P | 1 |
| Yin, Q | 1 |
| Yu, H | 1 |
| Zhang, Z | 2 |
| Li, Y | 1 |
| Godugu, C | 1 |
| Patel, AR | 1 |
| Doddapaneni, R | 1 |
| Marepally, S | 1 |
| Jackson, T | 1 |
| Singh, M | 1 |
| Zhang, L | 1 |
| Wang, Y | 1 |
| Xia, T | 1 |
| Yu, Q | 1 |
| Zhang, Q | 1 |
| Yang, Y | 1 |
| Cun, X | 1 |
| Lu, L | 1 |
| Gao, H | 1 |
| He, Q | 1 |
| Cardinale, D | 1 |
| Sandri, MT | 1 |
| Colombo, A | 1 |
| Salvatici, M | 1 |
| Tedeschi, I | 1 |
| Bacchiani, G | 1 |
| Beggiato, M | 1 |
| Meroni, CA | 1 |
| Civelli, M | 1 |
| Lamantia, G | 1 |
| Colombo, N | 1 |
| Veglia, F | 1 |
| Casiraghi, M | 1 |
| Spaggiari, L | 1 |
| Venturino, M | 1 |
| Cipolla, CM | 1 |
| Otake, AH | 1 |
| Mattar, AL | 1 |
| Freitas, HC | 1 |
| Machado, CM | 1 |
| Nonogaki, S | 1 |
| Fujihara, CK | 1 |
| Zatz, R | 1 |
| Chammas, R | 1 |
| Papp, M | 1 |
| Li, X | 1 |
| Zhuang, J | 1 |
| Wang, R | 1 |
| Uhal, BD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pilot Study of Losartan to Reduce Radiation Induced Fibrosis in Breast Cancer Patients[NCT05637216] | Phase 2 | 40 participants (Anticipated) | Interventional | 2023-08-17 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for losartan and Cancer of Lung
| Article | Year |
|---|---|
Prevention of Atrial Fibrillation in High-risk Patients Undergoing Lung Cancer Surgery: The PRESAGE Trial.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Humans; Incidence; Losartan; Lung Neoplas | 2016 |
7 other studies available for losartan and Cancer of Lung
| Article | Year |
|---|---|
Reduction of Liver Metastasis Stiffness Improves Response to Bevacizumab in Metastatic Colorectal Cancer.
Topics: Angiogenesis Inhibitors; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhi | 2020 |
Combining losartan with radiotherapy increases tumor control and inhibits lung metastases from a HER2/neu-positive orthotopic breast cancer model.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Chemoradiotherapy; Female; Losartan; Lung Neoplasm | 2021 |
Regulating cancer associated fibroblasts with losartan-loaded injectable peptide hydrogel to potentiate chemotherapy in inhibiting growth and lung metastasis of triple negative breast cancer.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antibiotics, Antineoplastic; Cancer-Associated Fib | 2017 |
Inhalation delivery of Telmisartan enhances intratumoral distribution of nanoparticles in lung cancer models.
Topics: Administration, Inhalation; Animals; Antineoplastic Agents; Benzimidazoles; Benzoates; Cell Line, Tu | 2013 |
Suppression for lung metastasis by depletion of collagen I and lysyl oxidase via losartan assisted with paclitaxel-loaded pH-sensitive liposomes in breast cancer.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Collagen Type I; Drug Delivery Systems; Hydrogen-Ion Co | 2016 |
Inhibition of angiotensin II receptor 1 limits tumor-associated angiogenesis and attenuates growth of murine melanoma.
Topics: Angiogenic Proteins; Angiotensin II Type 1 Receptor Blockers; Animals; Cell Line, Tumor; Female; Hum | 2010 |
Angiotensin receptor subtype AT(1) mediates alveolar epithelial cell apoptosis in response to ANG II.
Topics: Adenocarcinoma; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Apoptosis | 2002 |